TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management. In keeping with FDA's recent draft Guidance on using Artificial Intelligence, the TNF-Renova partnership is analyzing data from 30,000 patients to identify high-risk patients. TNF plans to use these data to optimize appropriate patient recruitment, accelerating isomyosamine drug development.
'Our collaboration partner, Renova Health has used its AI and machine learning technology platform to analyze and identify optimal patient pools and study sites, enabling a swift and efficient progression of our study series over the coming months,' said Mitchell Glass, M.D., President and Chief Medical Officer of TNF Pharmaceuticals. 'This technology has allowed us to look at the constellation of underlying conditions, symptoms, acute events, and medications being taken across thousands of patients to identify specific patient subsets for which isomyosamine treatment may be most beneficial.'
Renova Health's proprietary AI and machine learning technology—including a cutting-edge natural language processing (NLP) and large language model (LLM) platform—offers key benefits to TNF Pharmaceuticals including the ability to quickly review thousands of patient records to identify a target population that may benefit from isomyosamine. This target population consists of patients who have underlying chronic diseases, such as diabetes, COPD, chronic kidney disease, or sarcopenia/frailty, have suffered an acute medical event associated with inflammation (such as a fall or bone fracture), and are taking GLP-1 medications.
'We are thrilled to collaborate with TNF Pharmaceuticals to advance precision medicine through our cutting-edge NLP, LLM, and AI platform,' said David Jacobs, CEO of Renova Health. 'Our technology transcends traditional big data analytics by creating highly specific patient personas, identifying optimal cohorts for isomyosamine based on underlying conditions, acute events, and medication profiles. Furthermore, our platform uncovers the nuanced impact of individual physician practices—such as varying diagnosis codes for GLP-1 prescriptions, like BMI versus diabetes—which can significantly influence cohort selection and study outcomes. This unparalleled precision enables TNF Pharmaceuticals to target patients who stand to benefit most, accelerating study timelines and enhancing therapeutic impact.'
About Renova Health
Renova Health partners with large clinic practices, hospital systems, and accountable care organizations to help deliver better patient outcomes at a lower cost. The key to Renova Health's success is its highly skilled, caring, and passionate Personal Health Advocates that create and nurture a personal, trusting relationship with patients that helps to uncover deeper insights and ultimately leads to superior healthcare outcomes. For more information, visit www.renovahealth.care.
About Isomyosamine
Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNF-α plays a causative role in the pathogenesis of various age-related diseases.
About TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.tnfpharma.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company's goals and expectations related to TNF-Renova partnership. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Stock Market Today: Market rises on China talks
Stock Market Today: Market rises on China talks originally appeared on TheStreet. Updated: 11:41 a.m. ET. Stocks reversed early losses after President Donald Trump and Chinese President Xi Jinping spoke for more than 90 minutes Thursday morning and agreed to a high-level meeting on trade disputes in the near future. The Standard & Poor's 500 Index was up 0.4% to 5,995. The Nasdaq Composite Index had risen 0.7% to 19,592. The Dow Jones Industrial Average was sporting a 0.3% gain to 42,561. The call also touched on Chinese reluctance to approve export licenses on rare earth minerals, critical components used in the manufacture of electric vehicles. No resolution was announced, however. Auto makers have been struggling to obtain enough of materials to make high-end magnets and have feared having to shut down assembly lines with the materials, especially dysprosium and terbium. Trump said the call came to "a positive conclusion." A week ago, the administration had charged China with stalling on trade talks. Trump named Treasury Secretary Scott Bessent, Commerce Secretary Howard Ludnick and Trade Representative Jamieson Greer to meet with Chinese counterparts to try to resolve problems. No date was set. Tesla () shares were down 3.2% to $321.11; they had been down as much as5%. Costco Wholesale () slipped 2.6% to $1,025 on signs sales growth was easing. Crude oil was higher to $63.44. Gold was off slightly. The 10-year Treasury yield had moved up to 4.395%. Updated: 10:06 a.m. The Standard & Poor's 500 Index was off 0.2% to 5,958. The Nasdaq Composite Index was off 0.1% to 19436. The Dow Jones Industrial Average was off 0.4%, or 159 points, to 42,283. Tesla shares were off, possibly in reaction to CEO Elon Musk's criticisms of the new tax bill. The market had little reaction to a report that President Donald Trump had had a phone call with Chinese Xi Jinping. The Chinese government reported the call, and few details were available. Futures trading suggested stocks will open modestly higher. The Standard & Poor's 500 Index was looking at a 14-point gain. The Nasdaq-100 Index was signaling a 48-point jump. The Dow Jones Industrial Average was surging to a possible 100-point jump at the open. Meanwhile, the U.S. trade deficit shrank to $61.6 billion in April, an steeper move than Wall Street had forecast. It had ballooned to a record in March as businesses rushed to stockpile ahead of President Donald Trump's tariff initial jobless claims unexpectedly rose last week to the the highest since October, adding to signs that the job market is cooling. Initial claims increased 8,000 to 247,000 in the week ended May 31, a period that included Memorial Day. Continuing claims, a proxy for the number of people receiving benefits, fell slightly to 1.9 million in the previous week. But Bloomberg News noted the number remains elevated. Both suggest a weakening jobs market ahead of Fridays monthly unemployment report. Happy Thursday. We're doing something a little different today. We're kicking off the Stock Market Today column with comments from Stephen 'Sarge' Guilfoyle's daily Market Recon. This is the type of great analysis he provides every day over in TheStreet Pro. It could have gotten ugly, one might have thought. The information started trickling out on Wednesday morning. It certainly wasn't pretty. There was no bouquet of flowers tossed down from on high to brighten the mood. There would be no aroma of freshly baked bread wafting across the street to disguise the wretched stench of decay. There would be no knight in shining armor that could arise from the shadows to defend the citizenry from their fears. Still, as the numbers hit publication... as viewpoints expressing pessimism spread ... equity markets hung in there, supported by demand for debt securities that suppressed yields. That suppressed interest rates. So, it was. So now, it has been written. Suddenly, after a spate of negative reports had taken stocks down from their early morning and mid-morning highs, bond traders started buying U.S. Treasuries. On Wednesday, the U.S. 10-Year note, our nation's benchmark debt security, went out paying just 4.36%, down 11 basis points for the day. The 2-Year Note yielded just 3.88% (-8 bps) by day's end. The prospect for lower interest rates going forward allowed stocks to breathe and hold their levels on a day that they might otherwise have suffered a bout of profit taking. Just a day after investors had seen the S&P 500 technically confirm last Thursday's bullish change of trend. Friday's Bureau of Labor Statistics Employment Report for May could still turn markets on their ear, Or not. The "big, beautiful bill" could pass. Or not. Talks between Pres. Trump and China's Pres. Xi could go well. Or not. Heads on a swivel, gang. Two sources of water. Clean socks. Full battle rattle. What impacted the markets on Wednesday? What's about to impact our marketplace? Let's go... Uh oh. On Wednesday morning, the ADP Report on private sector hiring for May showed just 37,000 jobs created during the month. This was the fewest jobs shown as having been created by this report for any single month in more than two years. This shows a deceleration from April's creation of 60,000 private sector jobs and badly missed the consensus view for 110,000 jobs created. This does not necessarily mean that Friday's Bureau of Labor Statistics print will be weak, but it could. Anything this ugly on Friday will not pass unnoticed by investors. The ISM Non-Manufacturing Index hit the tape at 49.9 (50 is the line in these surveys between expansion and contraction), just a few days after the ISM Manufacturing Index had crossed the tape at 48.5. The real worry for May is the component labeled "New Orders," which is the single most important item in any business survey. For the month New Orders printed at 46.4 for Services and 47.6 for Manufacturing. That's nasty. Inventories and Backlogged Orders both also showed decay. Didn't anything show expansion? Oh, you bet your tail something did. Inflation did. Prices printed at a red hot 68.7 for the services economy and a white hot 69.4 for the manufacturing economy. Does that mean that we'll see reacceleration of consumer level inflation for May? I would think this is likely. We'll almost certainly see that producer level inflation has come back to life. The Federal Reserve released their Beige Book on Wednesday afternoon. The Beige Book, for the new kids, is a central bank publication containing anecdotal economic information from across the Fed's 12 regional districts, released eight times a year ahead of policy decisions. The Fed will make its next decision on monetary policy on June 18. On overall economic activity: "Reports across the 12 Federal Reserve Districts indicate that economic activity has declined slightly since the previous report. Half of the Districts reported slight to moderate declines in activity, three Districts reported no change, and three Districts reported slight growth." Boston... "Economic activity decreased slightly overall." New York... "Economic activity in the Second District continued to decline modestly amid heightened uncertainty." Philadelphia... "Business activity declined modestly in the current Beige Book period, as it did in the last period." Minneapolis... "The District contracted slightly overall." Kansas City... "Overall activity declined moderately, driven by lower retail spending, a decline in the demand for single-family homes, and a slight contraction in manufacturing." San Francisco... "Economic activity slowed slightly." Elsewhere, Richmond, Atlanta and Chicago reported slight expansion, while Dallas, Cleveland and St. Louis reported no change in business activity. Fed Funds Futures markets trading in Chicago are now pricing in a 76% probability for a quarter-point rate cut on Sept. 17 and a 54% likelihood for another quarter-point rate cut on Oct. 29. That would be it for the year. Two more rate quarter-percentage point cuts are currently being priced in for 2026. The Congressional Budget Office, which is non-partisan, but not always correct, assessed the president's "big, beautiful bill" and reported on Wednesday its expectation that over 10 years the bill, if passed into law, would increase deficits by $2.4 trillion. There is a real concern over passage in the Senate now, with a number of fiscal conservatives fretting that the budget cuts in the bill don't go far enough and other senators showing dismay that these cuts go too far. I tend to agree with the fiscal hawks here, as that is my nature as an economist. That, my friends, is neither here nor there. What matters is that the U.S. Dollar Index traded lower on this news and that while Treasury securities showed strength due to weakness in the above economic news, that the long end of the spectrum of Treasury securities could become unanchored should the federal government continue to behave in a fiscally reckless manner. The weaker dollar would indeed be inflationary. On Wednesday, the S&P 500 closed essentially flat (+0.01%), while the Nasdaq Composite gained 0.32% thanks to a 1.39% run made by the Philadelphia Semiconductor Index. Marvell Technologies () and ON Semiconductor () led that group for the day. Otherwise, not a lot changed on Wednesday. The Dow Transports gave up 0.46%, while the small to midcap indices all gave back between 0.2% and 0.26%. Six of the 11 S&P sector SPDR ETFs closed out Wednesday's regular session in the green, led by the Communication Services () fund that only gained 0.64%. While only five of these funds closed in the red, Energy () gave up 1.95% as exploration, refining and pipeline stocks all took a pounding, and the Utilities () gave back 1.75%. Winners beat losers on the NYSE on Wednesday by just three issues. This was largely a 50/50 split. Winners did lead losers at the Nasdaq by a 6-to-5 margin. Advancing volume did take a nifty 65.5% share of composite Nasdaq-listed trade on Wednesday, but just a 45.8% share of composite NYSE-listed activity. Most importantly, on a day-over-day basis, aggregate trade contracted across NYSE-listings by 5.2% and across Nasdaq-listed securities by 3.7%. Aggregate trade across the membership of the S&P 500 also fell 9% short of the trading volume 50-day simple moving average for the index on Wednesday after falling just 4% short of that line in the sand on Tuesday. Does this render Wednesday's market as less significant that it might otherwise be? In short, technically, the answer is "yes." Price discovery is always more meaningful and more impactful when increased trading volume implies increased professional participation. Readers will see just how incredibly accurate technical analysis has been through this recent period. On Wednesday, the index, though quiet, did build on Tuesday's confirmation of Thursday's change in trend. Is Advanced Micro Devices () getting ready to make a serious run at industry leader Nvidia () ? Is Lisa Su getting ready to make a serious run at Jensen Huang? Maybe. Check out these past few moves that largely flew under the radar: June 4th: AMD announces the acquisition of open-source software company Brium in an effort to further its prowess in generative artificial intelligence. Terms of the deal were not disclosed. May 28th: AMD announced the acquisition of silicon photonics company Enosemi to boost co-packaging and the firm's prowess in generative AI. Terms of the deal were not disclosed. May 20th: AMD announced the divestiture of its ZT Systems, which is a data center manufacturing company for $3 billion. But the firm retained ZT's 1,200-person engineering team at a cost of about $1.6 billion or $1.33 million per engineer. This should improve AMD's competitiveness in the data center GPU market. My Conclusion? AMD is back among my top 10 holdings when ranked by weighting (number 10) after a long hiatus. We skipped much of the 2024 decline. Our net basis is currently $99.91. I expect to continue to buy the stock on weakness when that opportunity arises going forward. Nvidia remains my 15th heaviest allocation. I have no plans to add. 08:30 - Initial Jobless Claims (Weekly): Expecting 230K, Last 229K. 08:30 - Continuing Claims (Weekly): Last 1.919M. 08:30 - Balance of Trade (Apr): Last $-140.5B. 08:30 - Non-Farm Productivity (Q1-F): Flashed -0.8% q/q. 08:30 - Unit Labor Costs (Q1-F): Flashed 5.7% q/q. 10:30 - Natural Gas Inventories (Weekly): Last +101B cf. 12:00 p.m. - Speaker: Reserve Board Gov. Adriana Kugler. 1:30 - Speaker: Philadelphia Fed Pres. Patrick Harker. Before the Open: () (.52) After the Close: () (1.57), () (.81), () (2.60) At the time of publication, Guilfoyle was long AMD, NVDA equity. Stock Market Today: Market rises on China talks first appeared on TheStreet on Jun 5, 2025 This story was originally reported by TheStreet on Jun 5, 2025, where it first appeared.
Business Wire
39 minutes ago
- Business Wire
Johnson Fistel Investigates Quantum Computing: Long-Term Investors Encouraged to Reach Out
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a shareholder rights law firm, announces it is investigating potential breaches of fiduciary duties by certain directors and officers of Quantum Computing Inc. (NASDAQ: QUBT) ('QCI' or 'the Company') in relation to their obligations to the company's shareholders. Johnson Fistel, PLLP, a shareholder rights law firm, announces it is investigating potential breaches of fiduciary duties by certain directors and officers of Quantum Computing Inc. (NASDAQ: QUBT) ('QCI' or 'the Company') in relation to their obligations Share What can I do? If you are a current long-term QCI shareholder, you may have legal claims that may be brought on behalf of the company, against the company's directors and officers. If you wish to discuss this notice or your legal rights, please contact lead analyst Jim Baker (jimb@ at 619-814-4471. If emailing, please include a phone number. If you have continuously owned QCI shares, you can click or copy and paste the link below in a browser to join: What is this about? Recently a class action complaint was filed against QCI alleging that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) Defendants overstated the capabilities of QCI's quantum computing technologies, products, and/or services; (2) Defendants overstated the scope and nature of QCI's relationship with NASA, as well as the scope and nature of QCI's NASA-related contracts and/or subcontracts; (3) Defendants overstated QCI's progress in developing a TFLN foundry, the scale of the purported TFLN foundry, and orders for the Company's TFLN chips; (4) QCI's business dealings with Quad M Solutions, Inc. and millionways, Inc. both qualified as related party transactions; (5) accordingly, QCI's revenues relied, at least in part, on undisclosed related party transactions; (6) all the foregoing, once revealed, was likely to have a significant negative impact on QCI's business and reputation; and (7) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times. About Johnson Fistel, PLLP: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Colorado, and Idaho. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Yahoo
41 minutes ago
- Yahoo
Banner Capital Announces Fund I Recapitalization and Launch of Fund II
SALT LAKE CITY, June 5, 2025 /PRNewswire/ -- Banner Capital Management, LLC ("Banner") is pleased to announce the closing of a portfolio recapitalization into Banner Capital Fund I ("Fund I") and the launch of Banner Capital Fund II ("Fund II"). Fund I Fund I is a multi-asset continuation fund with over $400 million in capital commitments, formed to acquire interests in eight of Banner's pre-fund portfolio companies. Funds managed by Hamilton Lane (Nasdaq: HLNE) acted as lead investor and many of Banner's pre-fund investors retained a meaningful interest in the portfolio companies via participation in the new vehicle. The transaction was designed to provide additional time and capital to each portfolio company while also offering partial liquidity to pre-fund investors and crystalizing performance. Tanner Ainge, Founder & CEO of Banner, said, "We are excited to welcome Hamilton Lane as an investor in Fund I, alongside our long-time partners. We remain strong believers in the companies and leadership teams that are part of Fund I and are grateful to have more time to fully realize the value created—while also providing early investors with interim liquidity." Ryan Smith, Managing Director on the Secondary Investment Team at Hamilton Lane, added, "We are proud to support these Banner portfolio companies through this next phase of growth. This transaction underscores Hamilton Lane's innovative approach, significant scale and deep experience in delivering strategic solutions for both GPs and LPs while facilitating long-term value creation." Fund II Following the close of Fund I, which has unfunded capital reserved solely for follow-on investments, Banner is also pleased to announce the launch of Fund II, a lower middle market buyout fund with a $200M target. Banner held a preliminary closing on Fund II to facilitate the recently-announced Western Pavement Services transaction. The Larry H. & Gail Miller Family Foundation, along with certain other legacy LPs, participated in this deal-driven closing. A traditional first closing is anticipated in Q4 2025. Tyler Price, Managing Director of Banner, stated "The target size for Fund II, along with our initial investment in Western Pavement Services, underscores Banner's deep commitment to the lower middle market, the Intermountain West, and to supporting founder- and family-owned businesses." AdvisorsBanner was advised by Harris Williams as financial advisor and Kirkland & Ellis LLP as legal counsel on the transaction. Hamilton Lane was advised by Debevoise & Plimpton LLP. About Banner CapitalBanner Capital Management, LLC is a private equity firm focused on providing partnership capital to family-owned and founder-led businesses across the Western United States. The firm invests in the industrial, services, consumer, and healthcare sectors. As of the closing of the Fund I transaction, Banner has $653 million in assets under management (AUM)* For more information, visit * The reported AUM figure includes (i) the 12/31/2024 valuations for the portfolio company securities managed by Banner at that time, plus (ii) the cost basis of the Western Pavement Services transaction which closed on 4/30/2025, plus (iii) the cost basis of an acquisition by Averra Holdings in connection with the Fund I closing, plus (iv) the value of the securities of certain rollover holders or co-investors which were contributed into Fund I, plus (v) the unfunded commitments which were received in connection with the Fund I transaction. This press release does not constitute an offer to sell, or the solicitation of an offer to purchase any security. Any investment involves substantial risks, including complete loss of capital. There can be no assurance that Banner will be able to implement the strategy described herein or, if implemented, it will lead to investor returns. Similarly, there can be no assurance Banner will be able to maintain the advantages discussed herein over time or outperform third parties or the financial markets generally. There can be no assurance that historical trends will continue. Certain information contained herein constitutes "forward-looking statements." Forward looking statements are subject to a number of known and unknown risks and uncertainties, including without limitation changes in economic conditions, political changes, international conflicts, legal and regulatory requirements, interest rate fluctuations, as well as changes in the markets, prospects and competition. Fund II only will be offered to qualified investors through its private placement memorandum and agreement of limited partnership, which contain a discussion of important risks and potential conflicts of interest, and this press release is qualified in its entirety by reference to such documents. About Hamilton LaneHamilton Lane (Nasdaq: HLNE) is one of the largest private markets investment firms globally, providing innovative solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 760 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has approximately $958 billion in assets under management and supervision, composed of more than $138 billion in discretionary assets and more than $819 billion in non-discretionary assets, as of March 31, 2025. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit or follow Hamilton Lane on View original content to download multimedia: SOURCE Banner Capital Management Sign in to access your portfolio
